ASH 2022
Read the full Report (pdf)
American Society of Hematology 10–13 December 2022 New Orleans, LA, USA
Featured articles
CONTENTS
Online First
Acute Lymphoblastic Leukaemia
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL
High-dose methotrexate or standard interim maintenance in young patients with ALL?
Acute Myeloid Leukaemia
Excellent results for triplet regimen in FLT3-mutated AML
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML
Promising results for triplet therapy with magrolimab in AML
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?
Chronic Leukaemia
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL
Ibrutinib plus venetoclax displays long-term benefits in CLL
Multiple Myeloma
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial
Deep and durable responses for quadruple therapy in smouldering MM
Ultra-sensitive MRD assessment in MM with BloodFlow
CAR-Hematotox score proves useful in relapsed/refractory MM
Head-to-head: VMP versus Rd in transplant-ineligible MM
Lymphoma
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma
High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma
Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma
CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL
Myeloproliferative Neoplasms
Efgartigimod successful in immune thrombocytopenia
INCA033989: novel investigational agent for CALR-mutated MPN
Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN
Immune Thrombocytopenia
Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia
Various Topics
C1 inhibitor deficiency linked to thrombosis
Durable responses to gene therapy in haemophilia A
Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia
Neutrodiet: non-restricted diet is the preferred option after SCT
Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care
